Read more Esmee Koedoot Presents VitroScan’s Approach to Precision Oncology at LBSP TechTalk

17 March 2026

VitroScan presented at the March TechTalk at Leiden Bio Science Park, where Esmee Koedoot shared how the company is advancing precision oncology through predictive, patient-specific insights that support therapy selection to improve patient outcomes. The event brought together a diverse group of innovators from across the life sciences ecosystem, fostering valuable discussions and knowledge exchange.

Read more

Read more VitroScan Shares ChemoPredict Journey at Biotech Booster Annual Event

11 March 2026

CEO Willemijn Vader and PSC Chair Joris Schuurmans highlighted lessons learned in the ChemoPredict Biotech Booster project from scientific innovation towards a market-ready solution.

Read more

Read more A Major Milestone for VitroScan: ISO 15189 Compliance! 🎉

10 March 2026

As of March 2026, VitroScan is operating under an ISO 15189 compliant quality management system. This internationally recognized quality standard sets the benchmark for excellence in medical laboratories, ensuring that every clinical sample analysis meets the highest levels of quality, reliability, and regulatory compliance.

Read more

Read more Info Sheet ADC efficacy assessment

1 December 2025

Download our Info sheet on ADC efficacy assessment in VitroScan's ex vivo micro-tumor platform

Read more

Read more Info Sheet Bispecific antibody testing

1 December 2025

Download our Info sheet on bispecific antibody efficacy assessment in VitroScan's ex vivo micro-tumor platform

Read more

Read more Our latest publication at a glance!

1 October 2025

Download our Info sheet on the latest VitroScan publication highlighting the predictive value of our platform

Read more

Read more AACR 2026

8 April 2026

Download our poster:

Read more

Read more VitroScan at SITC 2025

5 November 2025

Download our poster: Ex vivo micro-tumor testing identifies patient-specific anti-tumor immune responses to T cell engager ubamatamab

Read more

Read more VitroScan at ENA 2025

22 October 2025

Download our poster: Bispecific antibody ubamatamab induces patient-specific anti-tumor immune responses in an ex vivo platform for ovarian cancer

Read more

Read more Koedoot et al., npj Precision Oncology, 2025

30 August 2025

Publication of our study showing that VitroScan's 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.

Read more